Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma
International Journal of Molecular Sciences · 20.08.2024 · 25 (16) · 9022
DOI: 10.3390/ijms25169022 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2024. Verfasst von Weijun Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Cell Biology, West Virginia University, Morgantown, WV 26505, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, DNA Helicases, Gene Expression Regulation, Neoplastic, ATPases Associated with Diverse Cellular Activities. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Science Foundation, NIH NIGMS.
Abstract (Originalsprache)
Multiple myeloma is the second most hematological cancer. RUVBL1 and RUVBL2 form a subcomplex of many chromatin remodeling complexes implicated in cancer progression. As an inhibitor specific to the RUVBL1/2 complex, CB-6644 exhibits remarkable anti-tumor activity in xenograft models of Burkitt’s lymphoma and multiple myeloma (MM). In this work, we defined transcriptional signatures corresponding to CB-6644 treatment in MM cells and determined underlying epigenetic changes in terms of chromatin accessibility. CB-6644 upregulated biological processes related to interferon response and downregulated those linked to cell proliferation in MM cells. Transcriptional regulator inference identified E2Fs as regulators for downregulated genes and MED1 and MYC as regulators for upregulated genes. CB-6644-induced changes in chromatin accessibility occurred mostly in non-promoter regions. Footprinting analysis identified transcription factors implied in modulating chromatin accessibility in response to CB-6644 treatment, including ATF4/CEBP and IRF4. Lastly, integrative analysis of transcription responses to various chemical compounds of the molecular signature genes from public gene expression data identified CB-5083, a p97 inhibitor, as a synergistic candidate with CB-6644 in MM cells, but experimental validation refuted this hypothesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology & Cell Biology, West Virginia University, Morgantown, WV 26505, USA.
- Lane Department of Computer Science & Electrical Engineering, West Virginia University, Morgantown, WV 26506, USA.
- Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
- Department of Biochemistry and Molecular Medicine, West Virginia University, Morgantown, WV 26506, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morganton, WV 26506, USA.
- WVU Cancer Institute, West Virginia University, Morgantown, WV 26506, USA.
ORCID-Profile: Rachel S Mangano, Lori A Hazlehurst, Gangqing Hu
Förderung
- NIGMS NIH HHS
- National Science Foundation
- NIH NIGMS
- NSF
Zitieren
APA
Yi, W., Dziadowicz, S. A., Mangano, R. S., Wang, L., McBee, J., Frisch, S. M., Hazlehurst, L. A., Adjeroh, D. A., & Hu, G. (2024). Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma. International Journal of Molecular Sciences, 25(16), 9022. https://doi.org/10.3390/ijms25169022
Vancouver
Yi W, Dziadowicz SA, Mangano RS, Wang L, McBee J, Frisch SM, et al. Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma. International Journal of Molecular Sciences. 2024;25(16):9022. doi:10.3390/ijms25169022
BibTeX
@article{Yi2024,
author = {Yi, Weijun and Dziadowicz, Sebastian A and Mangano, Rachel S and Wang, Lei and McBee, Joseph and Frisch, Steven M and Hazlehurst, Lori A and Adjeroh, Donald A and Hu, Gangqing},
title = {Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {9022},
doi = {10.3390/ijms25169022}
}
EUVIMED